Number of the records: 1
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
- 1.0579078 - ÚMG 2024 RIV US eng J - Journal Article
Průková, D. - Anděra, Ladislav - Nahácka, Zuzana - Karolová, J. - Svaton, M. - Klánová, M. - Havránek, O. - Soukup, J. - Svobodová, K. - Zemanová, Z. - Tušková, D. - Pokorná, E. - Helman, K. - Forsterova, K. - Pacheco-Blanco, M. - Vočková, P. - Berková, A. - Froňková, E. - Trněný, M. - Klener, P.
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.
Clinical Cancer Research. Roč. 25, č. 14 (2019), s. 4455-4465. ISSN 1078-0432. E-ISSN 1557-3265
Institutional support: RVO:68378050
Keywords : acute myeloid-leukemia * open-label * cancer * landscape * combination * cytarabine * resistance * apoptosis * overcome * abt-199
OECD category: Biochemistry and molecular biology
Impact factor: 10.107, year: 2019
Method of publishing: Limited access
https://aacrjournals.org/clincancerres/article/25/14/4455/81919/Cotargeting-of-BCL2-with-Venetoclax-and-MCL1-with
Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over) expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of venetoclax resistance in MCL cells and tested strategies to overcome it.
Permanent Link: https://hdl.handle.net/11104/0347951
Number of the records: 1